Department of Hepatology, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine 75571 Paris Cedex 12, Paris, France.
Clin Res Hepatol Gastroenterol. 2011 Jun;35 Suppl 1:S21-30. doi: 10.1016/S2210-7401(11)70004-3.
Hepatocellular carcinoma (HCC) is the most frequent malignant tumour of the liver. HCC prognosis is dependent on the determination of the tumour stage by conventional imaging and early screening. However, patient survival can vary with the same tumour stage. Biomarkers thus have a role in providing an earlier diagnosis, better prognosis classification before treatment and classification prognosis during treatment. In this review article, we will provide a successive, detailed description of the serum, pathological, molecular and imaging markers of HCC.
肝细胞癌（HCC）是肝脏最常见的恶性肿瘤。HCC 的预后取决于常规影像学和早期筛查确定的肿瘤分期。然而，即使肿瘤分期相同，患者的生存情况也可能有所不同。因此，生物标志物在提供更早的诊断、治疗前更好的预后分类以及治疗期间的预后分类方面具有一定的作用。在这篇综述文章中，我们将详细描述 HCC 的血清、病理、分子和影像学标志物。
